O xidative stress is linked to the pathogenesis of age-related and chronic diseases, including atherosclerosis, cancer, etc. [1] [2] [3] Although well-controlled oxidative response has a protective role during acute inflammation and subsequent tissue repair, excessive oxidation exerts detrimental effects on tissues, thereby contributing to several pathologies. 4 Reactive oxygen species generated during inflammation modify a wide spectrum of targets resulting in accumulation of oxidized metabolic products. 2 Among substrates highly prone to oxidation are polyunsaturated fatty acids. Therefore, the formation and accumulation of lipid peroxidation (LPO) products is an inevitable consequence of oxidative stress in vivo. [5] [6] [7] During the considerable lifespan of humans, repeated oxidative stress combined with a virtually limitless source of substrates, exemplified by polyunsaturated fatty acids of plasma membranes, might ultimately result in accumulation of high levels of potentially harmful metabolic byproducts. 7, 8 The imbalance between the production and removal of harmful substances leads to impaired homeostasis.
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human pathologies. 10, [14] [15] [16] CEP-modified proteins 10, 13, 17, 18 and phospholipids 15 were shown to be elevated in patients with age-related macular degeneration (AMD) using both immunoassays 19, 20 and liquid chromatography-tandem mass spectrometry. 15 CEP levels are significantly elevated within the vessel wall of aging animals and in tumors with substantial inflammation.
14 Recent studies identified several CEP activities, including proangiogenic 14, 15 and proinflammatory 21, 22 functions. Stimulation of angiogenesis was shown to be mediated by tolllike receptor 2 (TLR2) on endothelial cells 14, 15 independently of vascular endothelial growth factor signaling. 14, 23 CEP was reported to stimulate macrophages to express several proinflammatory cytokines. 21, 22, 24 CEP adducts also promote platelet activation, granule secretion, and aggregation in vitro and thrombosis in vivo. 25 Collectively, CEP accumulation might contribute to several pathologies. Therefore, it is important to establish whether or not the highly active products of LPO can be further metabolized and cleared from the tissues.
Indeed, CEP level seems to be finely regulated in the physiological context, as it is dramatically increased at the early stage of wound healing, but returns to normal when the wound has healed.
14 It seems that after revascularization, CEP has been either degraded or metabolized. Although many macromolecules have fast rates of turnover, this mechanism does not seem to be applicable to CEP, where the pyrrole moiety is stabilized by aromaticity. Alternatively, scavenger cells, such as macrophages, might be involved in this process. 9, 20, 26, 27 Macrophages are highly heterogeneous, but can be generally placed into 2 major subtypes, proinflammatory M1 and anti-inflammatory M2; the latter are more efficient in scavenging activity because of higher expression of scavenger and mannose receptors. 26, 27 Peritoneal macrophages are often divided into 2 populations, F4/80 hi and F4/80 lo macrophages. 28, 29 F4/80 lo macrophages promote immune response through antigen presentation, whereas F4/80 hi macrophages are specialized for scavenging mainly through phagocytosis. 28 In this study, we show that CEP, but not structurally similar compounds, is specifically recognized and scavenged by macrophages; CD36, and, to a lesser extent, TLR2, are directly involved in this process. Deficiency in receptor-mediated CEP clearance causes CEP accumulation and increased angiogenesis in wounds.
Methods
Expanded Methods are presented in the Online Data Supplement.
Results

Differential Accumulation Patterns for CEP Modifications In Vivo
We first analyzed the pattern of CEP accumulation in wounds on the back of 8-week-old mice for a month. Although CEP was barely detectable in normal skin, its levels were dramatically increased in 3-day-old wounds, following a bell-shaped curve at later time points and returning to the normal levels at day 24 post injury, when wounds were almost completely healed ( Figure 1A ). Histological analyses revealed that CEP was highly localized in the scabs, granulation tissues, and hypertrophic epidermal wound edges at day 5, whereas at day 24, it was only present in the epidermis and hair follicles ( Figure 1B) . The transient nature of CEP presence in wounds and its rapid downregulation after completion of angiogenesis and the healing process indicate an existence of a specific mechanism of CEP clearance.
Because wound healing is a physiological process that restores original tissue integrity and functionality, we next assessed CEP accumulation in chronic pathological processes associated with continuous oxidative stress, such as tumor progression and atherosclerotic lesion development. 4, 30 CEP levels in melanomas were continuously increasing during tumor progression at 7, 14, and 21 days post implantation, whereas the tumor volume was increased by >60-fold within 2 weeks ( Figure 1C ; Online Figure  I ). Likewise, CEP was present at high levels in atherosclerotic lesions of Apoe −/− mice fed with a Western diet (WD) when compared with a control, in which there was no positive signal for CEP ( Figure 1D ). Moreover, the plasma CEP levels in these Apoe −/− mice were increased >8-fold when compared with controls, demonstrating that CEP presence in vivo was not limited to the atherosclerotic lesions but was a rather systemic response ( Figure 1E ). Plasma CEP levels in Apoe −/− mice were higher than those of wild-type (WT) mice even without a WD, however, a WD substantially augmented the oxidative processes resulting in at least 2-fold increase of CEP levels in blood of Apoe −/− mice ( Figure 1F ). After 18 weeks on a WD, CEP levels within the atherosclerotic lesions of Apoe −/− mice remained continuously high (Online Figure II) . Thus, the transient nature of CEP presence during wound healing is in contrast to its continuous accumulation in pathologies associated with inflammation and oxidative stress, implying the existence of a specific mechanism responsible for CEP degradation.
Besides the proangiogenic effect of CEP (Online Figure  III) , 14, 23 it has a proinflammatory role. 21, 22, 24 Indeed, in the presence of CEP, macrophages upregulated a proinflammatory cytokine, tumor necrosis factor-α, both at a protein ( Figure 1G ) as well as at an mRNA level ( Figure 1H ). Together with previous observations, this suggests that high levels of CEP might augment chronic pathological processes and emphasize an importance of the timely removal of this end product of LPO.
CEP Binding to Macrophages
To identify the cell type responsible for CEP clearance, we first tested the ability of various immune cells, such as R-MPMs (resident mouse peritoneal macrophages), bone marrow neutrophils, and lymph node T and B cells to bind to CEP directly. Based on fluorescence-activated cell sorting analysis, macrophages bound to hi macrophages bound to CEP in a concentration-dependent manner and the maximum binding of CEP-BSA to this cell population was at least 10× higher than to F4/80 lo macrophages based on fluorescence intensity ( Figure 2B ). F4/80 lo macrophages are a minor subset of R-MPMs, whereas >80% of total R-MPMs are F4/80 hi (Online Figure IVA) . MHC-II (major histocompatibility complex class II) expression is high on F4/80 lo macrophages, which are known to serve as antigen-presenting cells in vitro, but low on F4/80 hi macrophages (Online Figure IVB) . In contrast, scavenger receptors and pattern recognition receptors, such as CD36 and TLR2, respectively, are highly expressed on F4/80 hi macrophages (Online Figure 1 . Regulation of 2-(ω-carboxyethyl)pyrrole (CEP) levels in vivo. A, The presence of CEP-containing modifications in vivo during wound healing (n=5, top). The wounded skins were collected at the indicated times, homogenized, and then each supernatant was used for enzyme-linked immunosorbent assay (ELISA). CEP concentration was normalized by total protein concentration. Bottom, Representative images of wounds on the mouse back skins at the times indicated (n=5) are shown. B, Hematoxylin and eosin (H/E) and CEP immunofluorescence staining of the wounded skins at day 5 (5d) and 24 (24d) . Note that CEP is stained on the scabs, granulation tissues, and hypertrophic epidermal wound edges at day 5, whereas CEP is slightly stained in the epidermis and hair follicles at day 24. C, CEP accumulation in implanted B16-F10 murine melanomas was measured by ELISA. Melanomas were collected at day 7, 14, and 21 after subcutaneous injections of B16-F10 murine melanoma cells ( Figure IVB ), which are known to be involved in phagocytosis of apoptotic cells in vivo. 28 The concentration-dependent manner of CEP-BSA binding with a clear saturation together with differential interaction with distinct cell populations suggests the involvement of specific cell surface receptors. To rule out the possibility that the binding might be mediated by BSA but not by the CEP moiety, fluorescein isothiocyanate (FITC)-conjugated BSA (FITC-BSA) was used as a control. Fluorescence-activated cell sorting analysis showed that there were dose-dependently positive signals when CEP-BSA, but not FITC-BSA, was exposed to macrophages (Online Figure V) .
Next, we assessed whether exogenously provided CEP-BSA can interact with macrophages in vivo. Two hours after CEP injection, >80% of cells positive for CEP were also positive for CD68, a macrophage marker ( Figure 2C ). Thus, CEP is recognized by macrophages in vitro as well as in vivo.
Macrophages Are Able to Specifically Scavenge CEP But Not Similar Protein Modifications
To examine whether macrophages are able to scavenge and metabolize CEP, R-MPMs (that do not generate their own CEP) were incubated with exogenous CEP, washed, and the hi and F4/80 lo macrophages (B), which were incubated on ice for 30 minutes with CEP-bovine serum albumin (BSA) at the concentrations indicated, after freshly isolated from mouse bone marrow (for neutrophils), lymph nodes (for T and B cells), and peritoneum (for macrophages and B cells). Mean fluorescence intensity was normalized to that of 300 nmol/L CEP treatment, which was assigned a value of 100%. C, Immunofluorescence staining for CEP, CD68, and 4′,6-diamidino-2-phenylindole (DAPI) on the frozen sections of mouse back skins collected at 2 hours after intradermal injections of 10 μmol/L CEP-BSA or an equal amount of BSA as a control. Right, CEP presence in cells was measured by quantification of CEP/DAPI staining, whereas CEP presence specifically in macrophages was assessed based on CEP/CD68 costaining in tissues section (left). The value of CEP/DAPI costaining was assigned 100%. D and E, Immunostaining for CEP, CD68, and DAPI on the primary resident mouse peritoneal macrophages (R-MPMs) is shown. Cells were incubated at 37°C for the times indicated; then washed, culture media were changed with fresh media without CEP-BSA, and incubated for additional 0, 30, and 90 minutes after 30 minutes for pulse treatment (D) or during the entire incubation (E) with 500 nmol/L of CEP-BSA. F, CEP was quantified by enzyme-linked immunosorbent assay (ELISA) before and after incubation with macrophages. After 500 nmol/L CEP-BSA was added to the R-MPMs at 37°C, the supernatants were then collected at the times indicated, measured by ELISA, and normalized to the CEP only-containing culture media without macrophages. Percentage of remaining CEP is shown. Initial concentration of CEP (time point 0) was assigned a value of 100%. G, Simplified chemical structures of CEP and EP. H, Detection of ethylpyrrole (EP) by immunofluorescence in primary R-MPMs. In parallel, the staining for CD68 and DAPI is shown. R-MPMs were incubated at 37°C for the times indicated with 500 nmol/L of EP-BSA. Note that certain levels of EP are endogenously present in cells, but both binding and scavenging are lacking. Within the first 30 minutes of incubation, CEP was strongly present in R-MPMs, however, the CEP positive signal was gradually reduced at 30 minutes and finally disappeared at 90 minutes after media change, indicating that CEP was being scavenged by macrophages ( Figure 2D ). When macrophages were incubated with CEP for 24 hours without media change, all of the CEP had merged with CD68, known to be expressed in the lysosomes 31, 32 ( Figure 2E ), implying that CEP was scavenged and possibly metabolized by macrophages. The rate of CEP scavenging by macrophages was monitored by measuring the concentration of CEP remaining in the culture medium by ELISA. As macrophages actively bound and scavenged CEP, the CEP levels reached at approximately 70% of the initial concentration within 30 minutes and continued decreasing to approximately 20% of the original CEP amount within 24 hours ( Figure 2F ).
To investigate the specificity of CEP recognition and clearance, we compared it with that of a structurally similar protein modification, ethylpyrrole (EP). This protein modification is not only structurally similar to CEP (only lacking the carboxy group as shown in Figure 2G ), but it is cogenerated through an alternative oxidative cleavage of DHA to give 4-hydroxyhex-2-enal followed by condensation of 4-hydroxyhex-2-enal with the ε-amino group of lysyl residues (Online Data Supplement; Online Figure VIA) . We compared the interaction of EP-BSA and CEP-BSA with macrophages (Online Figure VIB) . As shown in Figure 2H , EP-BSA exhibited no binding to macrophages, which were not able to scavenge it for as long as 24 hours. Therefore, it seems that the process of recognition and scavenging by macrophages is highly specific for CEP-containing derivatives and it is not applicable to similar derivatives, such as EP-BSA modifications.
To demonstrate whether and how CEP is scavenged by macrophages in vivo, macrophages were depleted by clodronate treatment, 33, 34 resulting in at least 50% decrease in the amount of resident macrophages in skin ( Figure 2I ). Exogenous CEP was subcutaneously injected into control and macrophage-depleted mice, and amount of CEP in vivo was monitored. Although CEP levels in control mice were decreased in a time-dependent manner reaching ≈60% and 40% after 3 and 6 hours, respectively, there was a substantial delay in macrophage-depleted mice, where the levels were unchanged for at least 3 hours after CEP injection ( Figure 2J ). At the 6-hour time point, the remaining amount of CEP was about 2× higher in macrophage-depleted mice when compared with controls ( Figure 2J ). Collectively, these results demonstrate that CEP, a stable end-product of DHA oxidation, is scavenged by macrophages ex vivo and in vivo.
M2-Like Macrophages Efficiently Bind to and Scavenge CEP
As macrophages are mainly classified into 2 subtypes, M1 and M2, we examined whether 1 of these 2 populations preferentially bind to and scavenge CEP. To polarize macrophages toward M1-or M2-phenotypes, R-MPMs were treated by interferon-γ and lipopolysaccharide or interleukin-4, respectively, and the polarization was verified using known M1-or M2-markers. 27 Although M1-markers, Nos2 and Cxcl10, were remarkably increased in the M1-like macrophages; M2-markers, Chi3l3 and Cd36, were markedly increased on the M2-like macrophages ( Figure 3A ). Although M2-like macrophages were able to efficiently bind CEP, the M1-like macrophages exhibited relatively low binding ( Figure 3B ). CEP scavenging activity was also significantly lower for the M1-like macrophages compared with the M2-like macrophages ( Figure 3C ). These results indicate that both, CEP binding and scavenging, were primarily mediated by M2-like macrophages rather than by M1-like macrophages.
CEP Demonstrates Direct Interactions With CD36 and TLR2
As CEP was shown to bind to TLR2 on endothelial cells to induce angiogenesis, we examined whether TLR2 on macrophages serves as a possible receptor for CEP. Because TLR2 is known to partner with other receptors, such as CD14 and CD36, these receptors were also considered. CD36 is highly expressed by both F4/80 hi -and M2-like macrophages and is known to recognize several ligands, including modified lipoproteins, glycated proteins, and amyloid-forming peptides ( Figure 3A ; Online Figure IVD [35] [36] [37] ). Accordingly, we assessed CEP interactions with recombinant TLR2-Fc, CD36-Fc, and CD14-Fc chimeras in a solid phase immunoassay. Both, CD36 and TLR2, bound to CEP in a concentrationdependent manner, whereas binding to CD14-Fc and Fc Figure 4C and 4D) . The dissociation constants (Kd) for CD36 and TLR2 with CEP were 6.53 and 11.8 nmol/L, respectively. Since the functions of TLR2 depend on its association with either TLR6 or TLR1, where TLR6 is known to be involved in its partnership with CD36, 38 we assessed the direct binding of CEP to both TLRs using surface plasmon resonance. Although CEP interacted with both receptors (Online Figure VIIA-VIIC) , the binding to TLR6 was substantially higher than that to TLR1 and compatible to that to CD36. This was confirmed by ELISA (Online Figure  VIID) . CEP binding to Tlr6 −/− macrophages and the consequent intake was diminished compared with WT cells as evidenced by ≈30% decrease in average fluorescence intensity (Online Figure VIIE and VIIF) .
To further characterize the binding site for CEP on CD36, we performed a competition assay using a known ligand for CD36, oxidized low-density lipoprotein. 36 Oxidized low-density lipoprotein competed with CEP in a dose-dependent manner, indicating that CEP and oxidized low-density lipoprotein might share the same binding site on CD36 ( Figure 4E ). Indeed, 160 SLINKSKSSMF 170 peptide derived from an extracellular domain of human CD36 and known to be critical for oxidized low-density lipoprotein binding 39 inhibited CEP-CD36 interaction in a dose-dependent manner ( Figure 4F ).
CEP Scavenging Depends on CD36 and TLR2
The physical binding of CEP to CD36 was further confirmed by 2 different cell-based binding assays using stable cell lines expressing CD36, Raw264.7-CD36, and HEK293-CD36 (Online Figure VIII) . HEK293-CD36 cells bound about 3× more to CEP than control cells ( Figure 5A ). A similar trend was observed using Raw264.7-CD36 cells ( Figure 5B ). 40 Then, the role of CD36 in CEP clearance was tested using CD36-null (Cd36 −/− ) macrophages. When treated with CEP for 30 minutes, Cd36 −/− macrophages bound substantially less CEP than WT macrophages ( Figure 5C ). Moreover, Cd36
−/−-macrophages were defective in their ability to scavenge CEP. Although WT macrophages were able to metabolize about 40% of CEP in first 6 hours, CEP levels were not significantly changed in the presence of Cd36 −/− macrophages ( Figure 5D ). After 24 hours, WT macrophages were able to remove ≈85%, whereas Cd36 −/− macrophages metabolized only 40% of exogenously provided CEP ( Figure 5D ), indicating that CD36 on macrophages is essential for CEP binding and scavenging.
Similar experiments were conducted using Tlr2 −/− macrophages. Compared with WT, Tlr2 −/− macrophages bound less to CEP within 30 minutes ( Figure 5E ). Accordingly, CEP scavenging activity was also reduced in Tlr2 −/− macrophages since after 24 hours, remaining amounts of CEP were ≈15% for WT and 40% for Tlr2 −/− macrophages ( Figure 5F ). These experiments demonstrate that similar to CD36, TLR2 deficiency affects CEP binding and scavenging by macrophages, although the role of CD36 seems to be more prominent.
CEP Clearance Is Severely Impaired in CD36/TLR2 DKO Macrophages
Because CD36 often serves as a coreceptor for TLR2, 38, 41 we generated Cd36 , macrophages bound only 60% and 75% less to CEP than WT, respectively, the binding to DKO macrophages was reduced by about 90% when compared with WT ( Figure 6A and 6B) . Likewise, the amount of CEP scavenged by WT, Tlr2
, and DKO macrophages within 24 hours was 70%, 55%, 40%, and 22%, respectively ( Figure 6C ). Together, the additive effect of Tlr2 −/− and Cd36 −/− deficiencies suggests that while these receptors are both important for CEP binding and clearance by macrophages, they might function independently and the role of CD36 was more prominent.
Defective CEP Clearance Affects Angiogenesis and Wound Closure in CD36 Null Mice
To assess the importance of CEP presence and timely removal in tissues, we analyzed angiogenesis and wound healing in Cd36 −/− mice. Punch wounds were made on the back skin of 8-week-old WT and Cd36 −/− mice and monitored for 7 days. Surprisingly, at the early time points (day 3), wound closure was accelerated in Cd36 −/− mice when compared with WT, albeit no longer significantly at day 7 ( Figure 7A ; Online Figure  IXA) , which might be because of delayed clearance of apoptotic cells also mediated by CD36. 35 At the same time, CD31 immunostaining revealed that angiogenesis in Cd36 −/− wounds −/− wounds at day 3 by a multiphoton confocal microscopy revealed that CEP was localized inside of the cells in WT, but remained on the cell membrane in Cd36 −/− macrophages, implying defective scavenging ( Figure 7F and 7G) . Taken together, these results demonstrate that CD36 is absolutely required for CEP clearance in vivo. Cd36 −/− mice exhibit increased CEP accumulation, which, in turn, mediates the accelerated angiogenesis and wound closure.
Discussion
The key findings of this study are the following: First, a biologically active product of DHA oxidation, CEP, is continuously accumulated in pathologies exemplified by tumors and atherosclerotic lesions. During wound healing, however, CEP levels follow a bell-shaped curve returning to normal low levels when the wound is healed. In contrast to the accepted paradigm, CEP modifications are not the final and nondegradable products of DHA oxidation, they can be removed by F4/80 hi and M2-like macrophages ex vivo and in vivo. Second, this process is specific for CEP because the structurally similar modification, EP, was neither bound to nor degraded by macrophages. Third, this scavenging function is mediated by CD36 in cooperation with TLR2/TLR6, but not another TLR2 coreceptor, CD14. −/− DKO macrophages exhibit impaired abilities to bind to and scavenge CEP modifications. Fourth, the impaired CEP clearance in Cd36 −/− mice leads to accelerated angiogenesis and wound closure. Together, this provides a cellular and molecular mechanism controlling tissue levels of the highly biologically active LPO product, CEP, and establishes the pathophysiological importance of this process.
As an oxidation fragment of DHA, which is abundant in retina and brain, 42 CEP has been first shown to accumulate in retinas of patients with AMD. 16, 17, 43 Multiple studies from several laboratories demonstrated that CEP exerts both proangiogenic and proinflammatory activities potentially related to pathogenesis of AMD. 10, 15, 16, [21] [22] [23] [24] 44, 45 Moreover, the presence of CEP modifications as well as anti-CEP specific autoantibodies in plasmas of AMD patients were shown to serve as early signs of susceptibility to AMD, 46 thereby underscoring the role of oxidized DHA products in this disease. Furthermore, more recent studies revealed the presence and biological significance of CEP modifications in other physiological and pathological conditions, such as tumor growth, atherosclerosis progression, and thrombosis. 10, 14, 25 These studies emphasize an importance of the mechanism controlling CEP accumulation 
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in tissues and suggest that defective CEP clearance might play a causative role in pathologies. Indeed, here we show that delayed clearance of CEP in Cd36 −/− mice causes accelerated angiogenesis in vivo. Thus, the receptor-mediated CEP scavenging might serve as a potential therapeutic target for conditions associated with excessive oxidative stress, such as AMD or atherothrombosis.
The receptor-mediated specific recognition and clearance of LPO products in tissues represents a novel host defense mechanism which differs from well-known processes of reactive oxygen species neutralization by enzymatic and nonenzymatic antioxidants. 7 Interestingly, besides CEP, an alternative cleavage of DHA can give rise to EP, a modification similar to CEP. The only structural difference between CEP and EP is a presence of a carboxyl group in CEP, which seems to be essential for its recognition by macrophages. Thus, macrophages do not merely recognize any modified or denatured proteins, but bind to and scavenge a class of well-defined chemical moieties, that is, carboxyethylpyrrole, which might be present either on proteins 10 or lipids. 15 We demonstrate that macrophages are specifically responsible for CEP recognition and clearance. Our data suggest that macrophages might metabolize CEP in lysosomes after uptake because CEP staining is merged with that of CD68, a lysosome marker. 31, 32 This suggests that CEP, which is believed to be a stable end product of DHA oxidation can be further degraded. Moreover, differential CEP binding and scavenging activities of F4/80 hi versus F4/80 lo and M1-versus M2-like macrophages suggest that CEP clearance is mainly mediated by noninflammatory macrophages, but not by activated macrophages. [27] [28] [29] This is also supported by the results of in vivo wound healing experiments, where CEP is scavenged as early as at day 3 before the arrival of blood monocytes. The latter cells are known to express Ly-6C at high levels and F4/80 at low levels and to exhibit proinflammatory functions. [47] [48] [49] Wound macrophages undergo a transition from a high to a low level of Ly-6C as wound healing progresses, 50 supporting the idea that CEP clearance within the first 3 days is mainly mediated by resident macrophages. It seems that these macrophage populations might tip the balance toward either excessive or insufficient CEP levels, which, in turn, might define the spectrum and severity of angiogenic and inflammatory processes in vivo.
On macrophages, CEP binds to 2 main receptors, CD36 and TLR2, the latter has been shown to mediate activities of CEP-containing protein 14, 45 as well as lipid 15 modifications on other cell types. The fact that the defects of DKO macrophages were more severe than those of Cd36 −/− or Tlr2 −/− macrophages supports a possibility that CD36 and TLR2 play independent roles in CEP clearance. Interestingly, in contrast to many other ligands of TLR2, such as Pam3CSK4 and Lipoteichoic acid, this process does not involve CD14. 51, 52 Instead, it depends on CD36, another TLR2 coreceptor, known to mediate TLR2/TLR6 rather than TLR2/TLR1 functions. 52 In agreement with previous studies, 38, 41 it seems that during the scavenging of CEP modifications, CD36 operates with TLR2/TLR6 heterodimers, whereas the CEP signaling seems to be dependent on TLR2/TLR1. 15, 45 Also known as a scavenger receptor, CD36 recognizes misfolded proteins and specific lipid modifications, 35 including intermediate products of DHA oxidation, which serve as precursors of CEP and are known to play a causative role in atherosclerosis and thrombosis. 36, 53 Similar to TLR2, the recognition of CEP by CD36 is highly specific for carboxyalkylpyrrole because EP modifications are not recognized by either receptor. Therefore, CD36 might play a dual role in the metabolism of DHA oxidation products and in the pathogenesis of atherosclerosis in general, first, by mediating foam cell formation and thrombosis triggered by intermediate products of DHA oxidation, and, second, by facilitating the removal of the end products of this oxidation pathway.
CD36, as a receptor for thrombospondin, has been shown to serve as a negative regulator of angiogenesis. 54 This function might be context dependent because thrombospondin-1/thrombospondin-2 DKO mice were reported not to exhibit increased vascularity or accelerated wound healing when compared with WT controls. 55 Moreover, both wound closure and leukocyte recruitment over a 9-day period after injury in Cd36 −/− mice were shown to be comparable with that in WT.
56 This is consistent with our study (Online Figure VIII) . However, 3 days after injury, wounds of Cd36 −/− mice had more CEP than WT, which, in turn, accelerated vascularization and wound closure. If CEP is neutralized, these differences were no longer apparent, thereby demonstrating a causative role for CEP in this process. It might be plausible that at the later time points other CD36-dependent functions, including removal of apoptotic cells by macrophages, might slow down the wound closure rate in Cd36 −/− mice when compared with WT. Nevertheless, delayed CEP clearance in Cd36 −/− mice leads to accelerated angiogenesis and faster wound closure during the early and important phase of wound healing. In conclusion, this study underscores the role of endogenous metabolites of LPO in pathophysiology and demonstrates that the cellular processes naturally controlling their levels in tissues might serve as promising targets for the development of future therapeutic interventions. What Is Known?
• Reactive oxygen species generate a range of secondary toxic products from phospholipids, including carboxy ethyl pyrrole (CEP).
• CEP has been shown to promote vascularization and inflammation.
• CEP is believed to be a final and stable product of phospholipid oxidation; implying that it could accumulate in tissues for years.
What New Information Does This Article Contribute?
• Proteins modified by oxidized phospholipid products, CEP, are only transiently present during wound healing, whereas they are continuously accumulated in atherosclerotic lesions and growing tumors.
• These oxidation products are recognized, scavenged, and metabolized by macrophages, which control CEP levels in tissues.
• CEP, but not structurally similar modifications, bind to CD36 toll-like receptors 2 and 6 with high specificity.
Oxidative stress is a key determinant of cardiovascular diseases and aging. It results in tissue accumulation of chemically modified products with both, physiological and pathological activities. Although some of these products are essential for tissue repair processes, their excessive accumulation could lead to tissue injury. We found that CEP modifications are recognized and metabolized by tissue macrophages. During wound healing, tissue macrophages are responsible for the clearance of CEP modifications. This process is highly selective for CEP products and it involves specific innate immunity receptors on macrophages. This detoxification process represents a novel natural defense mechanism against uncontrolled accumulation of oxidized chemicals.
SUPPLEMENTAL MATERIAL.
Online Finally, CEP concentrations were measured by reading absorbance at 415 nm by using spectroscopy after the plates were washed and incubated with HRP substrates (ABTS, Invitrogen). TNF-α was measured from supernatants of thioglycolate-elicited mouse peritoneal macrophages, which were stimulated by CEP-BSA or control BSA for 4 hours, using mouse TNF-α DuoSet (R&D systems, Minneapolis, MN), according to the manufacturer's instructions.
Production and characterization of new monoclonal antibodies to CEP
Mice were injected with CEP conjugated to BSA using complete Freund's adjuvant (Sigma).
Two additional injections were done, 3 weeks apart using incomplete Freund's adjuvant. A final boost of CEP-BSA was performed without adjuvant 5 weeks later. Serum titer was determined by ELISA using CEP-KLH as a substrate for antibody selection. In this manner, the antibody selected is expected to be specific for CEP-modification, and not for the protein carrier (BSA).
The spleen from the mouse with the highest titer was isolated and used for the fusion in 
Surface Plasmon Resonance (SPR)
Real time protein-protein interactions were analyzed using a Biacore3000 instrument (Biacore, Uppsala, Sweden). CD36-Fc, TLR2-Fc, TLR1-Fc, TLR6-Fc and Fc-only control were immobilized on the CM5 biosensor chip using the standard amine coupling chemistry (1000 RU/flow cell). As an alternative approach, CEP-HSA was immobilized on the CM5 biosensor chip. Experiments were performed at RT in 10 mM HEPES (pH 7.4) buffer containing 150 mM NaCl and 0.005% surfactant P20 at a flow rate of 20 l/min. SPR sensograms were obtained by injecting various concentrations of analytes. In some samples analytes were preincubated with specific inhibitors for 10 min at RT. The chip surfaces were regenerated by injecting a short pulse of 25 mM NaOH. The resulting sensograms were analyzed in overlay plots using BIAevaluation software (version 4.01, GE Healthcare).
Wound healing assay
Mice were anesthetized by intraperitoneal injections of ketamine and xylazine, the back was shaved, and two 6 mm diameter full-thickness wounds were made using a sterile biopsy punch (Miltex, York, PA). For histological analysis, each wound was excised at the times indicated.
For CEP blocking antibody injection, Cd36 -/-mice were intravenously injected with a mouse IgM, isotype control antibody (Biolegend) or a mouse CEP monoclonal antibody (5 µg per g body weight) on the days 0, 1, and 2 after injury. All animal procedures were approved prior to the study by the Institutional Animal Care and Use Committee of Cleveland Clinic.
Histology and Immunofluorescence
For immunohistochemistry, tissues were fixed in 4% paraformaldehyde in PBS, embedded A 2-ethylpyrrole antigen was prepared by an approach used previously to raise polyclonal rabbit antibodies against a 2-pentylpyrrole bound to a carrier protein through an ε-aminocaproic acid linker. 1 Thus, an antigen was prepared by conjugating the activated ester of ethylpyrollated caproic acid (EP-CA) with a carrier protein, keyhole limpet hemocyanin (KLH) (Scheme S2).
Scheme S2. Synthesis of EP-C-KLH antigen and EP-BSA and EP-HSA. Nucleophilic 1,4-addition of nitropropane to acrolein at 0 °C gives 4-nitrohexanal (1). 2 Protection of the aldehyde as a dimethylacetal by treatment with montmorillonite K10 and trimethylorthoformate 3 gives 2. A variation of the Neff reaction converts the nitro group into a ketone 2, 4 producing 4-oxo-1,1-dimethoxyhexane (3). Deprotection of the latter and condensation 4-oxohexanal (4) with 6-aminocaproic acid gaves the acid (EP-CA).
1 Sodium Nhydroxysuccinimide sulfonate (HOSuSO 3 Na) was used for activation of EPCA, and reaction of 5 with KLH 1 gave the desired antigen (EP-C-KLH).
Ehrlich assay. The pyrrole concentration in these EP-protein derivatives (similar to CEP derivatives) was analyzed by Ehrlich's assay using 4-(dimethyamino)benzaldehyde (DMAB) and 6-(2-ethylpyrrol-1-yl)caproic acid (EP-CA) as standard. Absorbance at 540 nm was attributed to the formation of a purple chromophore from the α-substitution of the pyrrole by DMAB under acidic conditions. 7, 8 This assay assumes that both the standard EP-CA-derived chromophore and the protein adduct-derived chromophores have the same extinction coefficient. The results of Ehrlich assay combined with the results from BCA assay are given in Table S1 Calibration curves for the Ehrlich and BCA assays are shown in Figures S2 and S3 respectively.
Specificity of anti EP-C-KLH antibody.
To raise an antibody against EP-C-KLH specific to the ethyl pyrrole (EP) epitope, we also prepared the 4-oxohexanal-derived protein modifications, EP-BSA and EP-HSA, to serve as coating agent and standard respectively. To assess the structural specificity of the anti EP-C-KLH antibodies, the ability of various compounds to competitively inhibit antibody binding to EP-BSA was systematically examined.
Relative binding affinities of the EP-C-KLH antibody in competitive ELISAs using ethylpyrrolehuman serum albumin (EP-HSA) as a standard were determined as for the analogous pentylpyrrole-(PP-HSA) 1 and CEP-HSA derivatives (Scheme S2). Anti-EP-C-KLH antibody was shown to be specific for detecting EP-but not PP-or CEP-modified proteins. It showed less that 0.05% cross reactivity with either analogous pyrrole derivative, i.e., PP-or CEPmodified proteins. Samples for ELISA crossreactivity studies were prepared as follows: Table S1 and the calibration curves are presented in Figures S2 and S3 .
EP-BSA and EP-HSA. A solution of 4-oxohexanal (7.4 mM) and either BSA or HSA (0.01 mM), final concentrations, in a mixture of 6 mL of 10 mM sodium phosphate buffer (pH 7.4) and 2 mL of EtOH was incubated at room temperature for 4 h, and then dialyzed twice (24 h each) against 1L of 10 mM PBS (pH 7.4). The EP protein adducts were characterized by Ehrlich's assay and BCA protein assay.
